Skip to content

A study to see if using Platelet-Rich Fibrin (PRF) helps heal long standing non-healing wounds in patients

Role and Efficacy of Platelet-Rich Fibrin (PRF) in Management of Chronic Non-Healing Wounds - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094318
Enrollment
36
Registered
2025-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L974- Non-pressure chronic ulcer of heeland midfoot

Interventions

Intervention1: Platelet-Rich Fibrin: Platelet-Rich Fibrin (PRF)is prepared by procuring around 10 to 30 ml of blood depending on the wound size in a sterile vial and the vial is centrifuged at 3000 Ro

Sponsors

Vardhman mahavir medical college and safdarjung hospital, delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of age between 18 and 60 years with wounds that have persisted for atleast 4 weeks of various etiologies, such as diabetic ulcers, venous ulcers, pressure sores, or ischemic ulcers, small post burn wounds without significant improvement despite standard care. 2. Patients with stable systemic conditions allowing wound treatment. 3. Patients who have not responded to at least one standard wound care protocol prior to the intervention

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
To assess the effectiveness of PRF in reducing wound size and accelerating healing time in chronic non-healing wounds.Timepoint: Weekly for 9 weeks

Secondary

MeasureTime frame
To evaluate the impact of PRF on wound bed preparation, including granulation tissue formation and re-epithelialization.Timepoint: Weekly for 9 weeks; To analyse the role of PRF in reducing wound-associated complications such as infection and exudate.Timepoint: Weekly for 9 weeks; To assess patient satisfaction and quality of life after PRF treatmentTimepoint: At end of treatment; To document any adverse effects or challenges encountered during the use of PRFTimepoint: throughout the course of treatment

Countries

India

Contacts

Public ContactAmrita More

Vardhman mahavir medical college and safdarjung hospital

dr.amrita47@gmail.com9074037720

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026